ProCE Banner Activity

How Tirzepatide May Expand Treatment Options for Type 2 Diabetes

Clinical Thought
The dual GIP/GLP-1 receptor agonist has demonstrated efficacy in lowering A1C and body weight in the phase III SURPASS trials. Here’s my take on how it may fit into the treatment toolbox for type 2 diabetes.

Released: September 21, 2021

Expiration: September 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Partners

Endocrine Society

ProCE Banner